Market Potential of Carbon Dioxide Nasal Spray

NCT02113449 | Completed Phase 2 Results

• 2 other identifiers: 202181RH01910
• Study Type: interventional
• Target: 147
• Locations: 1 country
• Sites: 4

Brief Summary

Carbon dioxide (CO2) is a naturally occurring gas that readily diffuses across body tissues and membranes. Data from earlier clinical studies conducted in 975 subjects with allergic rhinitis have shown that nasally administered CO2 may provide relief of the associated symptoms. Symptom relief has been shown to occur as soon as 10 minutes after administration, and may persist for four to six hours. This study aims to assess the consumer appeal of a prototype CO2 delivery device, as well as evaluate its perceived effectiveness for nasal congestion. Properly consented subjects who qualify and choose to participate in the clinical study will be administered nasal CO2 under medical supervision, wait a period of 1 hour in clinic, and then be dispensed a device for self-treatment at home. Subjects will return to the clinic on day 7 for final evaluation and completion of assessment questionnaires.

Conditions

Nasal Congestion

Keywords

Carbon Dioxide, Allergy symptoms

Outcome Measures

Primary Outcomes (11)

• Which One Product That Relieves Nasal Congestion do You Buy Most Often?

  There was one questionnaire used in this study which was divided into 3 parts: screening survey, after product trial questions, and at home usage experience. This question was asked as part of screening survey prior to concept viewing. If the participant answered "I do not purchase any product to relieve congestion" the participant was excluded. Participants could select only one option available.

  7 days

• Which of the Statements Best Describes the Extent to Which the Spray Reached Your Expectations?

  There was one questionnaire used in this study which was divided into 3 parts: screening survey, after product trial questions, and at home usage experience. This question was asked after the first use. Participants could select only one option.

  7 days

• If the Product You Just Tried (After First Dose) Was Available for the Following Price: $12.99 for 40 Doses, How Likely Would You be to Buy it?

  There was one questionnaire used in this study which was divided into 3 parts: screening survey, after product trial questions, and at home usage experience. This question was asked after the first dose of the product. Participants could select only one option.

  7 days

• Would You be Interested in Taking the Spray Product Home and Using it Over the Next Week?

  There was one questionnaire used in this study which was divided into 3 parts: screening survey, after product trial questions, and at home usage experience. This question was asked after the first dose of the product. Participants could select only one option.

  7 days

• Which of the Following Statements Best Describes the Extent to Which the Spray Reached Your Expectations?

  There was one questionnaire used in this study which was divided into 3 parts: screening survey, after product trial questions, and at home usage experience. This question was asked after at-home use of the product. Participants could select only one option.

  7 days

• Divide 11 Points Between Two Products (CO2 Nasal Spray and Brand Selected at Q1)?

  There was one questionnaire used in this study which was divided into 3 parts: screening survey, after product trial questions, and at home usage experience. This question was asked after at-home use of the product. Participants could select only one option. It was done to compare the spray with the product selected by the participant in Q1. There were 11 points between the two products that participants could divide anyways thet wanted (11-0, 10-1, 9-2, 8-3, 7-4 or 6-5 etc). The more the participant liked a product compared to other, the higher the number of points were to be given to that product.

  7 days

• If the Product You Just Tried (After At-home Use) Was Available for the Following Price: $12.99 for 40 Doses, How Likely Would You be to Buy it?

  There was one questionnaire used in this study which was divided into 3 parts: screening survey, after product trial questions, and at home usage experience. This question was asked after at-home use of the product. Participants could select only one option.

  7 days

• How Many Packages Would You Buy?

  There was one questionnaire used in this study which was divided into 3 parts: screening survey, after product trial questions, and at home usage experience.This question was asked after at-home use of the product. Participants could select only one option.

  7 days

• Which One Statement Best Describes How Often, if Ever, You Think You Would Buy the Spray Product in the Future?

  There was one questionnaire used in this study which is divided into 3 parts: screening survey, after product trial questions, and at home usage experience. This question was asked after at-home use of the product. Participants could select only one option.

  7 days

• How Often do You Think This Spray Product Would Last for You Personally?

  There was one questionnaire used in this study which is divided into 3 parts: screening survey, after product trial questions, and at home usage experience. This question was asked after at-home use of the product. Participants could select only one option.

  7 days

• Provide a Score From 1-7 to Some Statements, Depending on How Much You Think Each Statement Applies or Does Not Apply to the Spray Product That You Used

  A score of 1 indicates that the statement does not apply at all to the product that you used. A score of 7 indicates that it applies completely to it. You can use any score from 1 to 7 to indicate how much or how little you think the statement applies to this product

  7 days

Study Arms (1)

Treatment Group

EXPERIMENTAL

Participants will receive one dose of nasal carbon dioxide (CO2) in the study clinic under medical supervision, followed by an additional six days of at home use, up to 4 times per day.

Drug: Carbon Dioxide

Interventions

Carbon Dioxide DRUG

Nasal administration of carbon dioxide (CO2) through the delivery device for 10 seconds

Treatment Group

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Participant who demonstrate understanding of, and willingness to participate in the study
• Aged at least 18 years.
• Understands and is willing, able and likely to comply with all study procedures and restrictions.
• Good general and mental health with, in the opinion of the investigator or medically qualified designee
• Participant has perception of Nasal Breathing score ≤70 mm (Visual Analogue Scale) on the evaluation day
• Females of childbearing potential who are, in the opinion of the investigator, practising a reliable method of contraception.

You may not qualify if:

• Women who are known to be pregnant or who have a positive pregnancy test, or who are intending to become pregnant over the duration of the study.
• Women who are breast-feeding.
• Known or suspected intolerance or hypersensitivity to the study materials (or closely related compounds) or any of their stated ingredients.
• Participation in another clinical study or receipt of an investigational drug within 30 days of the screening visit.
• Recent history (within the last 2 years) of alcohol or other substance abuse.
• Medical history of significant respiratory impairment.
• No history of product purchase for treatment of nasal congestion

Sponsors & Collaborators

• GlaxoSmithKline: lead

Study Sites (4)

Radiant Research - Chandler, AZ

Chandler, Arizona, 85224, United States

Location

Radiant Research - Pinellas Park, FL

Pinellas Park, Florida, United States

Location

TKL Research Inc

Paramus, New Jersey, 07652, United States

Location

Radiant Research - Cincinnati

Cincinnati, Ohio, 45249, United States

Location

Related Publications (1)

• Johnson SM, Hamilton AM, Lauersen LA. A phase IV, single-center, crossover evaluation of the efficacy of an external nasal dilator strip in children with nasal congestion. Allergy Asthma Proc. 2016 May;37(3):242-7. doi: 10.2500/aap.2016.37.3950.

  PMID: 27178892 DERIVED

MeSH Terms

Conditions

Nasal Obstruction

Interventions

Carbon Dioxide

Condition Hierarchy (Ancestors)

Nose Diseases; Respiratory Tract Diseases; Airway Obstruction; Respiratory Insufficiency; Respiration Disorders; Otorhinolaryngologic Diseases

Intervention Hierarchy (Ancestors)

Carbon Compounds, Inorganic; Inorganic Chemicals; Gases; Oxides; Oxygen Compounds

Results Point of Contact

• Title: GSK Response Center
• Organization: GlaxoSmithKline

866-435-7343

Study Officials

• GSK Clinical Trials

  GlaxoSmithKline

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 6, 2014
• First Posted: April 14, 2014
• Study Start: November 1, 2013
• Primary Completion: February 1, 2014
• Study Completion: February 1, 2014
• Last Updated: April 30, 2015
• Results First Posted: October 7, 2014

Record last verified: 2015-04

Locations

US (4)